Ignite Creation Date:
2025-12-24 @ 4:17 PM
Ignite Modification Date:
2026-02-18 @ 12:08 AM
Study NCT ID:
NCT02077166
Status:
COMPLETED
Last Update Posted:
2022-02-04
First Post:
2014-02-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
Pharmacyclics LLC.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
PCYC-1123-CA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None